(Q36573892)

15 August 2017

1 reference

title

A review of atypical antipsychotic drugs versus conventional medication in schizophrenia (English)

1 reference

15 August 2017

0 references

David Taylor

2

0 references

author name string

Barrat Luft

series ordinal

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

13

1 reference

15 August 2017

page(s)

1739-1748

1 reference

Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

Atypical antipsychotics and weight gain--a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

A meta-analysis of the efficacy of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

Dropout rates in randomised antipsychotic drug trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

Body weight gain induced by antipsychotic drugs: mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

Clozapine-associated diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

Olanzapine-associated diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

Testing for diabetes in hospitalised patients prescribed antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

Sudden cardiac death and antipsychotic drugs: do we know enough?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

Antipsychotics and the risk of sudden cardiac death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

Antipsychotics and the risk of sudden cardiac death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

Thioridazine and sudden unexplained death in psychiatric in-patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

A pilot cross-over design study on QTc interval prolongation associated with sulpiride and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1739

10.1517/14656566.7.13.1739

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference